

## Hormone Products for Postmenopausal Use in the United States and Canada

Compiled by The North American Menopause Society

© The North American Menopause Society.

April 1, 2009

**Table 1. Oral ET Products for Postmenopausal Use  
in the United States and Canada**

Composition	Product Name	Available Dosages (mg)
conjugated estrogens (formerly conjugated equine estrogens)	Premarin	0.3, 0.45*, 0.625, 0.9, 1.25
synthetic conjugated estrogens, A	Cenestin*	0.3, 0.45, 0.625, 0.9, 1.25
	Congest**	0.3, 0.625, 0.9, 1.25, 2.5
	C.E.S**	0.3, 0.625, 0.9, 1.25
	PMS-Conjugated**	0.3, 0.625, 0.9, 1.25
synthetic conjugated estrogens, B	Enjuvia*	0.3, 0.45, 0.625, 0.9, 1.25
esterified estrogens	Menest*	0.3, 0.625, 1.25, 2.5
	Neo-Estrone**	0.3, 0.625, 1.25
17 $\beta$ -estradiol	Estrace	0.5, 1.0, 2.0
	various generics	0.5, 1.0, 2.0
estradiol acetate	Femtrace*	0.45, 0.9, 1.8
estropipate (formerly piperazine estrone sulfate)	Ortho-Est*	0.625 (0.75 estropipate, calculated as sodium estrone sulfate 0.625), 1.25 (1.5), 2.5 (3.0)
	Ogen** various generics	0.625 (0.75), 1.25 (1.5), 2.5 (3.0) 0.625 (0.75), 1.25 (3.0)

\* Available in the United States but not Canada.

\*\* Available in Canada but not the United States.

Products not marked are available in the United States and Canada.

**Table 2. Transdermal and Topical ET Products for Postmenopausal Use in the United States and Canada**

Composition	Product Name	Delivery Rate (mg/day)	Dosing
17 $\beta$ -estradiol matrix patch	Alora*	0.025, 0.05, 0.075, 0.1	twice weekly
	Climara	0.025, 0.0375*, 0.05, 0.075, 0.1	once weekly
	Esclim*	0.025, 0.0375, 0.05, 0.075, 0.1	twice weekly
	Estradot**	0.025, 0.0375, 0.05, 0.075, 0.1	twice weekly
	Menostar*	0.014	once weekly
	Oesclim**	0.05, 0.1	twice weekly
	Vivelle	0.05, 0.1*	twice weekly
	Vivelle-Dot*	0.025, 0.0375, 0.05, 0.075, 0.1	twice weekly
	various generics	0.1, 0.05	once or twice weekly
17 $\beta$ -estradiol reservoir patch	Estraderm	0.05, 0.1	twice weekly (patch cannot be cut)
17 $\beta$ -estradiol transdermal gel	EstroGel 0.06%* Estrogel 0.06%**	0.035	daily application; 1 metered pump delivers 1.25 g of gel containing 0.75 mg 17 $\beta$ -estradiol
	Elestrin 0.06%*	0.0125	daily application; 1 metered pump delivers 0.87 g of gel containing 0.52 mg 17 $\beta$ -estradiol
	Divigel 0.1%*	0.003, 0.009, 0.027	daily application; 3 strengths of packets provide 0.25, 0.5, or 1.0 g of gel
17 $\beta$ -estradiol topical emulsion	Estrasorb*	0.05 (2 packets)	daily application of 2 packets; 1 packet = 1.74 g of emulsion
17 $\beta$ -estradiol transdermal spray	Evamist*	0.021 mg per 90 mcL spray (metered-dose pump)	initial: 1 spray/d of 1.7% solution, increasing to 2-3 sprays/d if needed

\* Available in the United States but not Canada.

\*\* Available in Canada but not the United States.

Products not marked are available in the United States and Canada.

**Table 3. Vaginal ET Products for Postmenopausal Use in the United States and Canada**

<b>Composition</b>	<b>Product Name</b>	<b>Dosing</b>
<i>Vaginal Creams</i>		
17 $\beta$ -estradiol	Estrace Vaginal Cream*	initial: 2-4 g/d for 1-2 wk maintenance: 1 g/d (0.1 mg active ingredient/g)
conjugated estrogens (formerly conjugated equine estrogens)	Premarin Vaginal Cream	0.5-2 g/d (0.625 mg active ingredient/g)
esterified estrogens	Neo-Estrone Vaginal Cream**	2-4 g/d (1 mg active ingredient/g)
<hr/>		
<i>Vaginal Rings</i>		
17 $\beta$ -estradiol	Estring	device containing 2 mg releases 7.5 $\mu$ g/d for 90 days
estradiol acetate	Femring*	device containing 12.4 mg or 24.8 mg estradiol acetate releases 0.05 mg/d or 0.10 mg/d estradiol for 90 days ( <u>systemic levels</u> )
<hr/>		
<i>Vaginal Tablet</i>		
estradiol hemihydrate	Vagifem	initial: 1 tablet/d for 2 wk maintenance: 1 tablet twice/wk (tablet containing 25.8 $\mu$ g of estradiol hemihydrate equivalent to 25 $\mu$ g of estradiol)

\* Available in the United States but not Canada.

\*\* Available in Canada but not the United States.

Products not marked are available in the United States and Canada.

**Table 4. Progestogens Used for EPT  
in the United States and Canada**

Composition	Product Name	Available Dosages
<i>Oral Tablet: Progestin</i>		
medroxyprogesterone acetate	Provera, various generics	2.5, 5, 10 mg
norethindrone (formerly norethisterone)	Micronor, Nor-QD,* various generics	0.35 mg
norethindrone acetate	Aygestin,* various generics	5 mg
norgestrel	Ovrette*	0.075 mg
megestrol acetate	Megace, various generics	20*, 40 mg
<hr/>		
<i>Oral Capsule: Progesterone</i>		
progesterone (in peanut oil)	Prometrium	100, 200* mg
<hr/>		
<i>Intrauterine System: Progestin</i>		
levonorgestrel	Mirena	20 µg/day approx release rate (52 mg IUS has 5-yr use)
<hr/>		
<i>Vaginal Gel: Progesterone</i>		
progesterone	Prochieve 4%* Crinone 4%**	45 mg/applicator

\* Available in the United States but not Canada.

\*\* Available in Canada but not the United States.

Products not marked are available in the United States and Canada.

**Table 5. Combination EPT Products for Postmenopausal Use in the United States and Canada**

Composition	Product Name	Available Dosages (mg/day)
<i>Oral Continuous-Cyclic Regimen</i>		
conjugated estrogens (E) + medroxyprogesterone acetate (P) (E alone for days 1-14, followed by E + P on days 15-28)	Premphase*	0.625 mg E + 5.0 mg P (2 tablets: E and E + P)
<i>Oral Continuous-Combined Regimen</i>		
conjugated estrogens (E) + medroxyprogesterone acetate (P)	Prempro*	0.625 mg E + 2.5 or 5.0 mg P (1 tablet); 0.3 or 0.45 mg E + 1.5 mg P (1 tablet)
	Premplus**	0.625 mg E + 2.5 or 5.0 mg P (2 tablets: E and P)
ethinyl estradiol (E) + norethindrone acetate (P)	femhrt*	2.5 µg E + 0.5 mg P (1 tablet); 5 µg E + 1mg P (1 tablet)
	femHRT**	5 µg E + 1 mg P (1 tablet)
17β-estradiol (E) + norethindrone acetate (P)	Activella*	0.5 mg E + 0.1 mg P (1 tablet); 1 mg E + 0.5 mg P (1 tablet)
17β-estradiol (E) + drospirenone (P)	Angeliq*	1 mg E + 0.5 mg P (1 tablet)
<i>Oral Intermittent-Combined Regimen</i>		
17β-estradiol (E) + norgestimate (P) (E alone for 3 days, followed by E+P for 3 days, repeated continuously)	Prefest*	1 mg E + 0.09 mg P (2 tablets: E and E + P)
<i>Transdermal Continuous-Combined Regimen</i>		
17β-estradiol (E) + norethindrone acetate (P)	CombiPatch,* Estalis**	0.05 mg E + 0.14 mg P (9 cm <sup>2</sup> patch, twice/wk); 0.05 mg E + 0.25 mg P (16 cm <sup>2</sup> patch, twice/wk)
17β-estradiol (E) + levonorgestrel (P)	Climara Pro*	0.045 mg E + 0.015 mg P (22 cm <sup>2</sup> patch, once/wk)
<i>Transdermal Continuous-Sequential Regimen</i>		
17β-estradiol (E) + norethindrone acetate (P) (E alone for 2 wks, followed by E+P for 2 wks, repeated continuously)	Estalis Sequi**	0.05 mg E twice/wk (Vivelle 50 patch) for 2 wks, then 9 or 16 cm <sup>2</sup> Estalis patch twice/wk for 2 wks
	Estracomb**	0.05 mg E twice/wk for 2 wks, then 0.05 mg E + 0.25 mg P for 2 wks

\* Available in the United States but not Canada.

\*\* Available in Canada but not the United States.